The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Open accessAbstract
EZ Inhibition: Missense mutations in the core constituents of the genome packaging material, chromatin, have been implicated in several of human cancers. Nucleosomes are made up of histones, and a mutation of lysine 27 (K27) to methionine in the N-terminal tail of histone variants H3.3 and H3.1 has been identified in various pediatric gliomas. Lewis et al. (p. 857 , published online 28 March; see the Perspective by Morgan and Shilatifard ) show that the polycomb enzyme complex, which can epigenetically modify K27 by addition of a methyl group—and which is often a silencing signal—is itself potently inhibited by replacement of the H3.3/3.1 K27 by methionine. The inhibition of the EZH2 subunit causes an overall reduction of K27 methylation. Methionine mutants of other methylated lysine residues in histone H3 cause similar reductions in methylation levels of the cognate lysine, altering the epigenetic profiles of such cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, tumor cells with the K27M mutation exhibit low levels of H3K27me3 and aberrant gene silencing (4,(7)(8)(9).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previously, we found that only long, unbranched hydrophobic side chains containing methionine (M) and isoleucine (I) at lysine 27 (K27M and K27I) were capable of inhibiting PRC2 in vitro and decreasing H3K27me3 when expressed ectopically in cultured cells (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
In the citing paper
“Despite reports supporting a higher affinity of PRC2 for H3K27M as compared with wild-type H3 108-110 , H3K27M was often inversely correlated with PRC2 occupancy, challenging the idea that H3K27M sequesters PRC2 on chromatin 111,112 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [112]
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Interestingly upon loss of H3K27me3 these nucleosomes acquire H3K27ac resulting in the formation of H3K27M-K27ac heterotypic nucleosomes4 (Figure 1D and Supplementary Fig. 5B–C).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Although still functionally active, PRC2 catalytic property toward H3K27M containing nucleosomes is strongly inhibited4.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Collectively, these results strongly indicate that H3K27M in DIPG cells does not appear to recruit or sequester EZH2 (or in general PRC2), as suggested by other studies4,6,7.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Attempts to model H3.3K27M-driven HGG formation in vivo via genetic recombination in neural progenitor/stem cells (NPCs) in the postnatal brain failed to demonstrate tumor-driving activity”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
In the citing paper
“H3.3K27M has been shown to have gain-of-function activity inhibiting the Polycomb Repressive Complex 2 (PRC2) (Bender et al., 2013; Lewis et al., 2013), which in turn leads to a global reduction in H3K27me3 levels in primary tumors and tumor-derived primary cells.”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,476
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,281
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 880
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 719
Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 633
A Novel Mammalian Flavin-dependent Histone Demethylase
Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, C., & Mattevi, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.003087 · Cited by 274
Flagged first, then by citations
Cited by
Sorted by citations
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
Self-citationKim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Epigenetic Determinants of CancerPreprint
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,414
Genome Regulation by Polycomb and Trithorax: 70 Years and Counting
Schuettengruber, B., Bourbon, H.-M., Di Croce, L., & Cavalli, G. (2017) · Cell · doi:10.1016/j.cell.2017.08.002 · Cited by 1,094
Metabolic regulation of gene expression through histone acylations
Sabari, B. R., Zhang, D., Allis, C. D., & Zhao, Y. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.140 · Cited by 1,168
Self-citationWu, G., Li, Y., Qu, C., Chen, X. '., Edmonson, M. N., Ma, X., Nagahawatte, P., Hedlund, E., Rusch, M., Huether, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,126
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2021) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 818
Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq
Filbin, M. G., Tirosh, I., Hovestadt, V., Shaw, M. L., Escalante, L. E., Mathewson, N. D., Neftel, C., Frank, N., Pelton, K., Hebert, C. M., et al. (2018) · Science · doi:10.1126/science.aao4750 · Cited by 694
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Castel, D., Philippe, C., Calmon, R., Dret, L. L., Truffaux, N., Boddaert, N., Pagès, M., Taylor, K. R., Saulnier, P., Lacroix, L., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1478-0 · Cited by 674
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A. J., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 671
Methionine metabolism in health and cancer: a nexus of diet and precision medicine
Sanderson, S. M., Gao, X., Dai, Z., & Locasale, J. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0187-8 · Cited by 601
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Mohammad, F., Weissmann, S., Leblanc, B., Pandey, D. P., Højfeldt, J. W., Comet, I., Zheng, C., Johansen, J. V., Rapin, N., Porse, B. T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4293 · Cited by 535
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Self-citationThe roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 556
The impact of cellular metabolism on chromatin dynamics and epigenetics
Reid, M. A., Dai, Z., & Locasale, J. W. (2017) · Nature Cell Biology · doi:10.1038/ncb3629 · Cited by 515
Epigenetic balance of gene expression by Polycomb and COMPASS families
Piunti, A., & Shilatifard, A. (2016) · Science · doi:10.1126/science.aad9780 · Cited by 524
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma
Taylor, K. R., Mackay, A. G., Truffaux, N., Butterfield, Y. S. N., Morozova, O., Philippe, C., Castel, D., Grasso, C. S., Vinci, M., Carvalho, D. M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2925 · Cited by 535
Regulation of chromatin and gene expression by metabolic enzymes and metabolites
Li, X., Egervári, G., Wang, Y., Berger, S. L., & Lu, Z. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0029-7 · Cited by 501
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
Fontebasso, A. M., Papillon-Cavanagh, S., Schwartzentruber, J., Nikbakht, H., Gerges, N., Fiset, P.-O., Bechet, D., Faury, D., De Jay, N., Ramkissoon, L. A., et al. (2014) · Nature Genetics · doi:10.1038/ng.2950 · Cited by 465
Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma
Hashizume, R., Andor, N., Ihara, Y., Lerner, R., Gan, H., Chen, X., Fang, D., Huang, X., Tom, M. W., Ngo, V., et al. (2014) · Nature Medicine · doi:10.1038/nm.3716 · Cited by 476
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Piunti, A., Hashizume, R., Morgan, M. A., Bartom, E. T., Horbinski, C. M., Marshall, S. A., Rendleman, E. J., Ma, Q., Takahashi, Y.-H., Woodfin, A. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4296 · Cited by 445
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 478
Pfister, S. X., Ahrabi, S., Zalmas, L., Sarkar, S., Aymard, F., Bachrati, C. Z., Helleday, T., Legube, G., Thangue, N. B. L., Porter, A. C. G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.026 · Cited by 496
Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 458
Solomon, D. A., Wood, M. D., Tihan, T., Bollen, A. W., Gupta, N. M., Phillips, J. J., & Perry, A. (2015) · Brain Pathology · doi:10.1111/bpa.12336 · Cited by 449
Chromatin proteins and modifications as drug targets
Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 448
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I. V., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.83 · Cited by 441
Resetting Epigenetic Memory by Reprogramming of Histone Modifications in Mammals
Zheng, H., Huang, B., Zhang, B., Xiang, Y., Du, Z., Xu, Q., Li, Y., Wang, Q., Ma, J., Xu, P., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.032 · Cited by 439
The roles of histone variants in fine-tuning chromatin organization and function
Martire, S., & Banaszynski, L. A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0262-8 · Cited by 392
Self-citationHistone Variants and EpigeneticsPreprint
Henikoff, S., & Smith, M. M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019364 · Cited by 445
The language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00357-x · Cited by 420
Self-citationStructural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2
Justin, N., Zhang, Y., Tarricone, C., Martin, S. R., Chen, S., Underwood, E., Marco, V. D., Haire, L. F., Walker, P. A., Reinberg, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11316 · Cited by 427
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402
Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation
Funato, K., Major, T., Lewis, P. W., Allis, C. D., & Tabar, V. (2014) · Science · doi:10.1126/science.1253799 · Cited by 390
Self-citationTranscriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 400
Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape
Lü, C., Jain, S. U., Hoelper, D., Béchet, D., Molden, R. C., Ran, L., Murphy, D. A., Venneti, S., Hameed, M., Pawel, B., et al. (2016) · Science · doi:10.1126/science.aac7272 · Cited by 406
Self-citationThe expanding landscape of ‘oncohistone’ mutations in human cancers
Nacev, B. A., Feng, L., Bagert, J. D., Lemiesz, A. E., Gao, J., Soshnev, A. A., Kundra, R., Schultz, N., Muir, T. W., & Allis, C. D. (2019) · Nature · doi:10.1038/s41586-019-1038-1 · Cited by 384
Self-citationThe landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
Huether, R., Dong, L., Chen, X. '., Wu, G., Parker, M. D., Wei, L., Ma, J., Edmonson, M. N., Hedlund, E., Rusch, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms4630 · Cited by 391
Kundu, S., Ji, F., Sunwoo, H., Jain, G., Lee, J. T., Sadreyev, R. I., Dekker, J., & Kingston, R. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.009 · Cited by 333
Pediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y., Gupta, N. M., Hawkins, C. E., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 372
Self-citationHarutyunyan, A. S., Krug, B., Chen, H., Papillon‐Cavanagh, S., Zeinieh, M. P., Jay, N. D., Deshmukh, S., Chen, C. C. L., Belle, J. I., Mikael, L. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09140-x · Cited by 367
Self-citationMorgan, M. A., & Shilatifard, A. (2020) · Nature Genetics · doi:10.1038/s41588-020-00736-4 · Cited by 374
Buczkowicz, P., Bartels, U. K., Bouffet, É., Becher, O. J., & Hawkins, C. E. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1319-6 · Cited by 356
Self-citationKorshunov, A., Ryzhova, M. V., Hovestadt, V., Bender, S., Sturm, D., Capper, D., Meyer, J., Schrimpf, D., Kool, M., Northcott, P. A., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1405-4 · Cited by 353
Maze, I. S., Noh, K., Soshnev, A. A., & Allis, C. D. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3673 · Cited by 376
Self-citationZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression
Wen, H., Li, Y., Xi, Y., Jiang, S., Stratton, S. A., Peng, D., Tanaka, K. Y., Ren, Y.-F., Xia, Z., Wu, J., et al. (2014) · Nature · doi:10.1038/nature13045 · Cited by 358
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Wainwright, E. N., & Scaffidi, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.004 · Cited by 348
Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management
Sturm, D., Pfister, S. M., & Jones, D. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0242 · Cited by 346
Regulation of gene transcription by Polycomb proteins
Aranda, S., Martín, G. M., & Croce, L. D. (2015) · Science Advances · doi:10.1126/sciadv.1500737 · Cited by 358
Variants of core histones and their roles in cell fate decisions, development and cancer
Buschbeck, M., & Hake, S. B. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.166 · Cited by 362
H3K27 methylation: a promiscuous repressive chromatin mark
Wiles, E. T., & Selker, E. U. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.11.001 · Cited by 347
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Suvà, M. L., & Tirosh, I. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.001 · Cited by 334
Histone Chaperones: Assisting Histone Traffic and Nucleosome Dynamics
Gurard‐Levin, Z. A., Quivy, J., & Almouzni, G. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035536 · Cited by 333
PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells
Kaneko, S., Son, J., Shen, S. S., Reinberg, D., & Bonasio, R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2700 · Cited by 319
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A. R., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 373
Larson, J. D., Kasper, L. H., Paugh, B. S., Jin, H., Wu, G., Kwon, C.-H., Fan, Y., Shaw, T. I., Silveira, A. B., Qu, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.015 · Cited by 312
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Pfister, S. X., Markkanen, E., Jiang, Y., Sarkar, S., Woodcock, M., Orlando, G., Mavrommati, I., Pai, C., Zalmas, L., Drobnitzky, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.015 · Cited by 323
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma
Jones, C., & Baker, S. J. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3811 · Cited by 304
Karremann, M., Gielen, G. H., Hoffmann, M., Wiese, M., Colditz, N., Warmuth‐Metz, M., Bison, B., Claviez, A., van Vuurden, D. G., von Bueren, A. O., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox149 · Cited by 298
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 291
From profiles to function in epigenomics
Stricker, S. H., Köferle, A., & Beck, S. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.138 · Cited by 300
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas
Fang, D., Gan, H., Lee, J., Han, J., Wang, Z., Riester, S. M., Jin, L. G., Chen, J., Zhou, H., Wang, J., et al. (2016) · Science · doi:10.1126/science.aae0065 · Cited by 285
Characteristics of H3 K27M-mutant gliomas in adults
Meyronet, D., Esteban-Mader, M., Bonnet, C., Joly, M., Uro‐Coste, E., Benouaich‐Amiel, A., Forest, F., Rousselot‐Denis, C., Burel‐Vandenbos, F., Bourg, V., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now274 · Cited by 287
A new world of Polycombs: unexpected partnerships and emerging functions
Schwartz, Y. B., & Pirrotta, V. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3603 · Cited by 299
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 289
Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma
Nikbakht, H., Panditharatna, E., Mikael, L. G., Li, R., Gayden, T., Osmond, M., Ho, C.-Y., Kambhampati, M., Hwang, E. I., Faury, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11185 · Cited by 252
Souweidane, M. M., Kramer, K., Pandit-Taskar, N. D., Zhou, Z., Haque, S. S., ZANZONICO, P. B., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Pathania, M., De Jay, N., Maestro, N., Harutyunyan, A. S., Nitarska, J., Pahlavan, P., Henderson, S., Mikael, L. G., Richard-Londt, A., Zhang, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.014 · Cited by 264
PRC2 is high maintenancePreprint
Yu, J.-R., Lee, C., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 267
Korshunov, A., Capper, D., Reuss, D., Schrimpf, D., Ryzhova, M., Hovestadt, V., Sturm, D., Meyer, J., Jones, C., Zheludkova, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1493-1 · Cited by 236
Panwalkar, P., Clark, J. R., Ramaswamy, V., Hawes, D., Yang, F., Dunham, C. P., Yip, S. S. F., Hukin, J., Sun, Y., Schipper, M. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1752-4 · Cited by 250
Histones: At the Crossroads of Peptide and Protein Chemistry
Müller, M. M., & Muir, T. W. (2015) · Chemical Reviews · doi:10.1021/cr5003529 · Cited by 247
Self-citationMolecular architecture of human polycomb repressive complex 2
Ciferri, C., Lander, G. C., Maiolica, A., Herzog, F., Aebersold, R. H., & Nogales, E. (2012) · eLife · doi:10.7554/elife.00005 · Cited by 263
PRC2 mediated H3K27 methylations in cellular identity and cancer
Conway, E., Healy, E., & Bracken, A. P. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.003 · Cited by 250
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Bhat, K. P., Kanıskan, H. Ü., Jin, J. J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 250
Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas
Papillon‐Cavanagh, S., Lü, C., Gayden, T., Mikael, L. G., Béchet, D., Karamboulas, C., Ailles, L., Karamchandani, J., Marchione, D. M., Garcia, B. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3757 · Cited by 248
Self-citationKrug, B., Jay, N. D., Harutyunyan, A. S., Deshmukh, S., Marchione, D. M., Guilhamon, P., Bertrand, K. C., Mikael, L. G., McConechy, M. K., Chen, C. C. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.004 · Cited by 245
Self-citationZhao, S., Bellone, S., Lopez, S., Thakral, D., Schwab, C. L., English, D. P.-G., Black, J., Cocco, E., Choi, J., Zammataro, L. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614120113 · Cited by 232
Guo, R., Zheng, L., Park, J. W., Lyu, R., Chen, H., Jiao, F., Xu, W., Mu, S.-R., Wen, H., Qiu, J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.022 · Cited by 237
Causes of genome instability: the effect of low dose chemical exposures in modern society
Langie, S. A. S., Koppen, G., Desaulniers, D. M., Al‐Mulla, F., Al-Temaimi, R. A., Amedei, A., Azqueta, A., Bisson, W. H., Brown, D. G., Brunborg, G., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv031 · Cited by 239
Developmental origins and emerging therapeutic opportunities for childhood cancer
Filbin, M. G., & Monje, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0383-9 · Cited by 258
Targeting EZH2 in cancer therapy
Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 232
The interplay between DNA and histone methylation: molecular mechanisms and disease implications
Li, Y., Chen, X., & Lu, C. (2021) · The EMBO Reports · doi:10.15252/embr.202051803 · Cited by 223
Chromatin signatures of cancerPreprint
Morgan, M. A., & Shilatifard, A. (2015) · Genes & Development · doi:10.1101/gad.255182.114 · Cited by 218
The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
He, Y., Selvaraju, S., Curtin, M. L., Jakob, C. G., Zhu, H., Comess, K. M., Shaw, B., The, J., Lima-Fernandes, E., Szewczyk, M. M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2306 · Cited by 224
Black, J. C., Manning, A. L., Rechem, C. V., Kim, J., Ladd, B., Cho, J., Pineda, C. M., Murphy, N., Daniels, D. L., Montagna, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.051 · Cited by 220
Self-citationRole of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and CancerPreprint
Laugesen, A., Højfeldt, J. W., & Helin, K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026575 · Cited by 225
Nacev, B. A., Jones, K. B., Intlekofer, A. M., Yu, J., Allis, C. D., Tap, W. D., Ladanyi, M., & Nielsen, T. O. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0288-4 · Cited by 214
Self-citationLiu, I., Jiang, L., Samuelsson, E. R., Salas, S. M., Beck, A., Hack, O. A., Jeong, D., Shaw, M. L., Englinger, B., LaBelle, J. J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01236-3 · Cited by 225
Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA
Wang, X., Paucek, R. D., Gooding, A. R., Brown, Z. Z., Ge, E. J., Muir, T. W., & Cech, T. R. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3487 · Cited by 215
Self-citation
Metadata
- Authors
- Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D.
- Affiliations
- Rockefeller University (US)
- Princeton University (US)
- Duke University (US)
- University of Pennsylvania (US)
- Corresponding author
- Allis, C. David
- ORCID
- Venue
- Science
- Published
- 2013-05-17
- Volume
- 340
- Issue
- 6134
- Pages
- 857-861
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3951439
- OpenAlex
- W1995105508
- Cited by
- 1,345
- References
- 14
- Citations by year
- 2026: 73 · 2025: 82 · 2024: 103 · 2023: 106 · 2022: 103 · 2021: 118 · 2020: 146 · 2019: 112 · 2018: 84 · 2017: 102 · 2016: 90 · 2015: 95 · 2014: 87 · 2013: 40
- FWCI
- 51.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD007447)
- National Institute of Mental Health (P50MH096890)
- National Institute of General Medical Sciences (GM040922, R01GM107047, R01GM040922)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pediatric glioblastoma, diffuse intrinsic pontine glioma, H3K27M mutation, histone H3.3, H3K27me3, polycomb repressive complex 2, EZH2, histone methylation, gain-of-function mutations, epigenetic regulation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Brain Neoplasms, Child, Glioblastoma, Histones, Humans, Lysine, Methionine, Methylation, Transgenes, Amino Acid Substitution, Mutation, Missense, Epigenesis, Genetic, Mice, HEK293 Cells, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
